Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder characterized by a reciprocal chromosomal translocation t(9;22)(q34;q11.2), resulting in a BCR-ABL oncogenic fusion gene on the Philadelphia chromosome (Ph).
1,2 Allogeneic stem cell transplantation (SCT) is the only curative treatment, and 40-80% of patients remain disease free for more than 5 years post-SCT. 3 However, the recurrence of CML remains a major cause of treatment failure, and relapse occurs in about 20-30% of patients transplanted with non-T-cell-depleted marrow in the first chronic phase (CP1). 4 Several therapeutic options exist for patients who relapse following allogeneic SCT; immunosuppressant withdrawal, donor leukocyte infusion (DLI), interferon-a, and second transplantation. Most of these options are based on the stimulation of an allogeneic immune modulating reaction that causes a graft-versus-leukemia (GVL) effect. DLI has become the treatment of choice for relapsed CML, and results in complete remission in up to 75% of cases; moreover, these remissions are durable with a rate of almost 90% at 2-3 years. 5 As immunotherapy with DLI may be more effective if administered in the earlier stages of relapse, a more sensitive technique capable of detecting disease recurrence at an early stage could be of therapeutic benefit. Accordingly, molecular technologies, such as fluorescence in situ hybridization (FISH), reverse transcriptase-polymerase chain reaction (RT-PCR), and real-time quantitative RT-PCR (Q-RT-PCR) have replaced conventional cytogenetics and Southern blot in the monitoring of post transplant minimal residual disease (MRD). RT-PCR is the most sensitive of the molecular technology-based assays, but it is limited by its qualitative nature, and thus may not detect early relapse in individual patients. On the other hand, Q-RT-PCR correlates strongly with cytogenetics, FISH, RT-PCR, competitive RT-PCR, and Southern blot, [6] [7] [8] [9] [10] and its usefulness for MRD monitoring has been reported by many authors. 6, 11, 12 An important issue when deciding therapeutic intervention using results from Q-RT-PCR is: how should molecular relapse (MRel) be defined and at what level immunotherapy should be given? Another important issue is: how soon after transplantation can immunotherapy be given safely? The latter might be particularly important in patients who relapse within a few months of transplantation. Some data regarding immunotherapy for early-phase relapse exist, but the relapse time after transplant is variable as is the dose of T cells infused. 5, [13] [14] [15] [16] Accordingly, treatment results and the toxicities of early-period immunotherapy for early-phase relapse are not well known.
In this study, we monitored MRD using conventional cytogenetics, FISH, RT-PCR, and Q-RT-PCR in consecutive patients who received allogeneic SCT for CML in CP1, and analyzed the treatment outcomes of immunotherapy for early-phase relapse, as defined by the Q-RT-PCR level, during the early period after SCT.
Patients and methods

Patients and samples
From June 1999 to June 2001, 45 consecutive patients with BCR-ABL-positive CML in CP1 underwent myeloablative transplantation at the Catholic Hematopoietic Stem Cell Transplantation Center in Seoul. Using conventional cytogenetics, FISH, nested RT-PCR, and Q-RT-PCR, MRD was prospectively monitored from bone marrow (BM) samples in all cases at 1, 3, 6, 9, and 12 months post-SCT, and subsequently at 3-6-month intervals. In relapsed cases, MRD was more frequently assessed at 1-2-month intervals as needed. Written informed consent was obtained from each patient before enrolment in this study.
Study design
Patients who were diagnosed to have an MRel or a cytogenetic relapse (CRel), as described below, within 6 months after SCT were analyzed. Patients with MRel were randomly assigned to either a 'no-therapy' (group A) or an 'immunotherapy' (group B) arm. Immunotherapy was reserved until CRel in group A, but was given soon after MRel in group B. Immunotherapy was also given to patients relapsing directly into CRel without preceding MRel (Figure 1 ). When immunotherapy was decided upon, immunosuppression was withdrawn in any case receiving an immunosuppressive drug. DLI, if available, was given at a low dose (1.0 Â 10 6 /kg of CD3 þ lymphocytes) on a single occasion when normalized BCR-ABL transcripts did not decrease after 1 month of immunosuppressant withdrawal. Donor cells were collected on a continuous flow cell separator (COBE spectra, Gloucester, UK). The T cell dose administered was determined using a fluorescein isothiocyanate (FITC)-conjugated CD-3 specific monoclonal antibody (Leu 4; Becton Dickinson, Mountain View, CA, USA) using a FACScan cell analyzer (Becton Dickinson). Interferon-a was added to cases in which immunotherapy was not effective at reducing BCR-ABL transcripts or to those in whom additional DLI was not available. The primary end point of this study was to determine the effect upon disease progression of early immunotherapy for Q-RT-PCR-based MRel. The secondary end points were to evaluate the toxicity, survival rate, and remission rate of immunotherapy during the early period after transplantation.
Interphase FISH
Uncultured BM specimens of minimum volume 30 ml were immediately delivered to the laboratory and incubated in hypotonic potassium chloride. Following incubation, the cells were fixed with methanol/acetic acid (vol/vol, 3/1). Hybridization and detection were performed, as described by the manufacturer, using the m-BCR-ABL translocation DNA probe mixture (Cytocell, Banbury, Oxfordshire, UK). The m-BCR probes were digoxigenin labeled, and hybridization signals were detected using cy3-conjugated antidigoxigenin antibodies. The ABL probe was biotinylated and hybridization signals were detected using FITCconjugated streptavidin. Hybridization signals were evaluated using an epifluorescence microscope with triple-pass filters (Nikon E800, Nikon, Japan). At least 500 nuclei were counted in each sample. Nuclei with fused green and red or a yellow signal were interpreted as positive for the BCR-ABL translocation. We first performed FISH analysis on the BM of 20 healthy donors, after obtaining consent. False positive cells in BM were detected in 2.7570.83% (mean7s.d.) of 500 cells. Therefore, we defined a positive cut-off as the mean þ 3 s.d. or 5.24% based on the results obtained from healthy BM.
Total RNA isolation and cDNA synthesis Mononuclear cells from fresh BM aspirates were isolated by Histopaque density gradient centrifugation (Sigma, USA; density 1.077 g/ml). Total RNA was extracted from mononuclear cells using an RNAqueous Kit (Ambion Inc., USA). Reverse cDNA transcription was performed on 1 mg of total RNA and samples containing less than 1 mg of RNA were discarded. cDNA was synthesized from RNA and 3.2 mg of random p(dN) 6 primer in 20 ml of a solution containing 10 mM Tris (pH 8.3), 50 mM KCl, 5 mM MgCl 2 , 50 U RNase inhibitor, 1 mM dNTP Mix, and 20 U of AMV reverse transcriptase (Roche, Germany). The mixtures were incubated at 251C for 10 min and subsequently incubated at 421C for 1 h, and denatured by heating at 951C for 5 min.
PCR primers
A two-step nested procedure using two sets of primers was used for the nested RT-PCR amplification. The first PCR involved primers B1 -5 0 -gctacggagaggctgaagaa-3 0 located on bcr exon 11 -and A1 -5 0 -cgtgatgtagttgcttggga-3 0 located on ABL exon 3 (product sizes were as follows: b3a2, 627 bp; b2a2, 552 bp; c3a2, 1167 bp). The other primer set for the second PCR involved primers B2 -5 0 -gtgcagagtggagggagaac-3 0 located on bcr exon 13 -and A2 -5 0 -acaccattccccattgtgat-3 0 located on ABL exon 3 (product sizes were as follows: b3a2, 443 bp; b2a2, 368 bp; c3a2, 983 bp). Primer 3 software, as provided by the MRel were randomized to either 'no therapy' (group A) or 'immunotherapy' (group B). For patients relapsing directly into CRel, immunotherapy was given. w One patient was excluded from analysis due to transplant-related death.
Whitehead Institute for Biomedical Research/MIT Center (Cambridge, MA, USA), was used to design primers.
Nested RT-PCR
The first-round RT-PCR was carried out with 2 ml of cDNA, 50 pmol of B1 and A1 primers, 0.2 mM dNTP, 1.5 mM MgCl 2 , and 2.5 U of Taq DNA polymerase (Roche, Germany) in 1 Â PCR buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl) in a total volume of 50 ml. PCR conditions were as follows: initial denaturation at 941C for 3 min, then 30 cycles of amplification at 941C for 30 s, 631C for 30 s, and 721C for 30 s, followed by a final elongation step at 721C for 5 min. A measure of 5 ml of the amplified DNA from the first round was used as a template for the secondround PCR using B2 and A2 primer. Second-round PCR conditions were the same as those used in the first round, described above. After each amplification, 5 ml of the PCR product was electrophoresed through ethidium bromidestained 2% agarose gel and photographed. For all RT-PCR reactions, K562 cells were used as a positive control and HL60 cells as a negative control. Using this method, we were able to detect a single BCR-ABL positive K562 cell against a background of 10 6 HL60 cells.
Cloning and sequencing
Quantitation standards were prepared by cloning PCR products of the three BCR-ABL transcripts (b2a2, b3a2, and c3a2) and those of normal ABL. To purify the PCR products for cloning, amplified PCR products were run on an ethidium bromide-stained 2% agarose gel, and specific bands were excised and extracted using a Quantum Prep Gel Slice Kit (Bio-Rad, USA). Eluted DNA was cloned into the pCR 2.1-TOPO vector (Invitrogen, USA). Cloned plasmid DNA was prepared using the Quantum Prep Plasmid Miniprep Kit (Bio-Rad, USA) using a modified alkaline lysis method and sequenced with M13 forward primer using an ABI Prism 310 automatic sequencer (Applied Biosystems, USA). Sequences were identified by the BLAST network service (National Center for Biotechnology Information, Bethesda, MD, USA). Finally, product absorbances were measured in a Smart Spec 3000 UV-Vis spectrophotometer (Bio-Rad, USA) and the concentrations calculated. In order to construct standard curves to quantify the BCR-ABL and ABL transcripts, serial dilutions were performed for all tests.
Primers and probes for real-time Q-RT-PCR
The BCR-ABL primers used for the RQ-PCR sequences were as follows: BCR-ABL sense (5 0 gatgctgaccaact cgtgtg3 0 ), BCR-ABL antisense (5 0 aacgaaaaggttggggtcat3 0 ) and the ABL primer sets used for normalizing BCR-ABL were as follows: ABL sense (5 0 gcctcagggtctgagtgaag3 0 ), ABL antisense (5 0 acaccattccccattgtgat3 0 ). The TaqMan probes, BCR-ABL (5 0 agaccctgaggctcaaagtcagatgctact3 0 ), and ABL (5 0 agagtgttatctccactggccacaaaatca3 0 ) were designed to hybridize to the antisense strand of each sequence. Probes were labeled with 6-carboxy-fluorescein phosphoramidite (FAM) at their 5 0 ends, and 5-carboxytetramethyl-rhodamine (TAMRA) was incorporated as a quencher at nt 13 (for BCR-ABL) or at nt 17 (for ABL) of the probe sequence; in addition, phosphate groups were attached to the 3 0 ends to prevent probe extension during PCR amplification (TIB Molbiol, Berlin, Germany). Primer 3 software was used to design primers for RQ-PCR, as provided by the Whitehead Institute for Biomedical Research/MIT Center.
Real-time Q-RT-PCR
Real-time PCR was performed on an iCycler using iCycler software 2.1 (Bio-Rad, USA). Optimal reaction conditions for amplifying both BCR-ABL and ABL were as follows: 50 cycles of a two-step PCR (951C 15 s, 601C 1 min) after an initial denaturation (951C 10 min). The 50 ml RQ-PCR reaction mixtures contained 4 ml of sample DNA, 1 Â PCR buffer, 0.2 mM of each dNTP (Roche, Germany), 4.5 mM MgCl 2 , 0.2 mM of each primer, 140 nM TaqMan probe, and 1.25 U AmpliTaq Gold DNA polymerase (PE Biosystems, USA). PCR reaction mixtures were set in an iCycler iQ 96-well PCR plate (Bio-Rad, USA), which was sealed using iCycler optical quality sealing tape (Bio-Rad, USA). RQ-PCR experiments were performed in duplicate, but if the BCR-ABL/ABL values were discordant by more than two-fold or inconsistent with the RT-PCR result, the procedure was repeated. When the Q-RT-PCR sensitivity was studied in serial 10-fold dilutions (from 1 to 10
À6
) of the K562 cell line, diluted in HL60 cells, the method was capable of detecting one single K562 cell among 10 000 background cells. Ten-fold aqueous dilutions of cDNA obtained by RT of RNA from K562 cells in the same range (from 1 to 10 À6 ) were also used to test the sensitivity of the method. A dilution of 10 À5 was detectable when 1 mg of RNA was transcribed. For all RQ-PCR reactions, K562 cells were used as a positive control and HL60 cells as a negative control. BCR-ABL expression was normalized vs normal ABL expression for quantification purposes. BCR-ABL and normal ABL expression were quantified using a 7 log series of standards of pBCR-ABL and pABL plasmid DNA between 0.4 ng and 0.4 fg. The standards were aliquoted into 30 ml lots and stored at À701C. iCycler optical software 2.1 was used to produce a standard curve by plotting the C T (threshold cycle) vs a known quantity on a logarithm scale, and unknown samples were quantified by interpolation. To calculate the amounts of the normal ABL transcript present, the amount of BCR-ABL transcript was subtracted from the total amount of the ABL transcript. Results are expressed as BCR-ABL/ABL ratios.
Definition of relapse and remission
Hematological relapse was diagnosed on the basis of standard hematological criteria. CRel was diagnosed at any time when any Ph metaphases or positive FISH results of at least 500 cells were detected without evidence of hematological relapse. MRel was defined as a BCR-ABL/ ABL ratio, as determined by Q-RT-PCR, exceeding 10 À2 without evidence of CRel or hematological relapse. Our previous study showed that Q-RT-PCR agreed well with first-round RT-PCR, but not with second-round RT-PCR. 10 Our purpose for defining MRel in the present study was to facilitate decision-making with respect to therapeutic intervention and immunotherapy soon after transplantation, taking into account the risk of severe toxicity, and we used a Q-RT-PCR cut-off level from firstround RT-PCR rather than from second-round RT-PCR. As the cut-off level of Q-RT-PCR for first-round RT-PCR positivity was 0.0189, we arbitrarily defined MRel as a BCR-ABL/ABL ratio exceeding 10
À2
. Complete cytogenetic remission (CCR) was defined as no Ph positive metaphase or negative FISH results. Molecular remission (MR) was defined as a negative nested RT-PCR conversion for BCR-ABL transcripts in consecutive tests at least 1 month apart.
Response and toxicity assessment
Patients were considered assessable for acute and chronic GVHD if they survived 30 and 100 days postimmunotherapy, respectively. Acute and chronic GVHD were graded using standard clinical criteria. 17, 18 Pancytopenia was defined by the occurrence of an absolute neutrophil count of less than 500/ml, and/or a platelet count of less than 20 000/ml, not deemed to be due to disease.
Statistical analysis
End points were calculated at the date of the last follow-up, which was 31 March 2003. Fisher's exact test and the Mann-Whitney test were employed to compare appropriate groups. Outcome probabilities, such as CRel, MR, and treatment-related mortality (TRM), were calculated using the Kaplan and Meier method and censored if a treatment other than immunotherapy was being administered, such as imatinib mesylate. All quoted P-values are two-sided and statistical significance was accepted at Po0.05.
Results
Patient characteristics
Relapse occurred within 6 months after transplantation in 18 patients and the initial relapse stage was MRel in 14 and CRel in four. One patient with MRel was omitted from the analysis due to transplant-related death soon after the diagnosis of relapse. The characteristics of the enrolled 17 patients are summarized in Table 1 . Their median age was 34 years (16-48) and 12 of the 17 patients were male. Disease duration before SCT was a median 7.6 months. Patients received BM from an HLA matched sibling (n ¼ 13) or unrelated donor (n ¼ 4). The pretransplant conditioning regimen was total body irradiation 12 Gy plus cyclophosphamide 120 mg/kg in all cases. GVHD prophylaxis consisted of short-term methotrexate plus cyclosporine (n ¼ 11) or tacrolimus (n ¼ 6). All 17 patients were on immunosuppressant therapy at the time of relapse. Patients with MRel were assigned to either group A (n ¼ 6) or group B (n ¼ 7). No significant differences in the pretransplant parameters were observed between these two groups. Normalized BCR-ABL transcript at 1-month post-SCT in all patients was a median 0.00026 (range, 0.000052-0.0089), but it was 0.013 (0.013-1.3) and 0.78 (0.017-3.8) at the time of diagnosing MRel and CRel, respectively.
Immunotherapy was effective in preventing disease progression from isolated MRel
MRel developed at a median 3.1 months post-SCT (range, 2.8-6.3 months). In group A, without immunotherapy, all six patients progressed to CRel within the following 3.0 months ( Table 2) . In group B, immunosuppressant withdrawal alone was given for three patients and DLI with or without interferon was added in the remaining four 2-14 days later. Compared to group A, CRel following MRel occurred in only Table 1 Characteristics of the enrolled patients (Figure 2a ).
Remission rate after immunotherapy was no different for MRel and CRel
In group A, immunosuppressant withdrawal alone was used in one patient and additive treatment with DLI with or without interferon in the remaining five patients. MR was achieved in four (67%) and persisted for 18.5-26.5 months. In group B, immunosuppressant withdrawal alone was used in three patients and additive treatment with DLI in the remaining four patients. MR was achieved in five patients (71%), but one (case 9) was diagnosed to have extramedullary relapse 14.8 months later. In the remaining four patients, MR persisted for 14.6-29.7 months. In nonresponders (cases 12 and 13), the disease progressed to CRel, which was followed by hematological relapse. The probability of MR as estimated by the Kaplan-Meier method was 100 and 78.6717.8% in group A and group B, respectively ( Figure 2b ).
Survival benefit was not achieved by early immunotherapy in MRel
Acute GVHD (XII) following immunotherapy was observed in two patients of each group. (Figures 2c and d) .
Lower remission rate was observed in patients progressing directly to CRel
CRel was initially diagnosed in four patients at 3.0-6.3 months post-SCT ( Table 2 ). All patients were given immunotherapy and MR was achieved in two (50%). In case 14, a second DLI with a dose of 1 Â 10 7 /kg was given for hematological relapse, but it was not effective.
Treatment results according to various treatment options
Overall, MR was achieved in 11 (64.8%) of the 17 enrolled patients at a median of 3.3 months (range, 1.2-11.4 months) after immunotherapy. The probability of MR after immunotherapy was 72.2712.5%. Immunosuppressant withdrawal alone was used for five patients and all achieved MR after extensive GVHD. After additive Table 2 Disease progression and treatment outcomes of immunotherapy for early-phase relapse defined by transcript level by Q-RT-PCR 
Cases
MRel and immunotherapy (group B) 
Discussion
Of the various technologies employed in this study, conventional cytogenetics is still considered the 'gold standard' in terms of evaluating transplant response in patients with CML. This technique, however, suffers from considerable drawbacks, because it requires cells in mitosis and is prone to sampling errors. 19 As FISH has been reported to be technically more sensitive than cytogenetics, and has been found to be useful for clinical monitoring after allogeneic SCT, 9 we also used FISH to detect the post transplant relapse. RT-PCR has been used for MRD detection after allogeneic SCT and most transplant centers have demonstrated that the majority of patients were PCR positive during the first 6 months after transplantation. Therefore, during this period PCR positivity could not be used to differentiate patients destined to relapse. 20 Because of these considerations, we used Q-RT-PCR to detect early relapse in the present study. As previously described, the definition of MRel used was based on a first-round RT-PCR cut-off level. The main reason why we chose a level higher than nested RT-PCR positivity was that we wished to reduce the risk of toxicity associated with the early period after transplantation. All patients having a normalized BCR-ABL above 10 À2 progressed to CRel without treatment, while those given immunotherapy had a significantly lower probability of CRel. Although this result suggests that patients with normalized BCR-ABL transcript levels of higher than 10 À2 within 6 months of transplantation should be treated to prevent disease progression, further studies are needed to validate significant levels below this threshold in terms of predicting relapse with respect to time after SCT. The results of this investigation also show that RQ-PCR is an essential tool for MRD monitoring and for managing early relapse after transplantation.
Even though disease progression to CRel was prevented by immunotherapy in isolated MRel, this effect did not result in MR rate and overall survival differences in the two study groups. Reserving DLI until CRel was not advantageous because two patients died of treatment-related toxicities, which might have been dependent on time after transplantation rather than upon a different treatment schedule. In contrast, immunotherapy in MRel failed to induce complete remission in 29% of patients, which might have been due to the rapidly relapsing nature of the disease. Accordingly, new approaches are needed to reduce complication levels, and more effective treatment options should be deeply considered for controlling rapidly advancing disease.
Regarding DLI, the majority of previous studies have employed a variable number of T cells and an inhomogeneous schedule, which prevented the correct assessment of response induced by T cell number. In the present study, a T cell number of 1 Â 10 6 /kg induced MR or CCR in eight (72.7%) of 11 patients who received DLI only once. This result could be used as a guide when deciding upon the T cell dose when DLI is planned. In addition to T cell dose, the toxicities of dosages should be considered, especially during the early period after transplantation. The incidence of GVHD has been correlated with the dose of T cells administered. 15 However, little information is available concerning the dose of T cells required to initiate GVHD according to time after transplantation. For example, it has been shown that as few as 1 Â 10 5 /kg T cells are capable of causing GVHD if given on the day of transplantation, 27 and 1 Â 10 6 /kg T cells are required 3-4 months after SCT. 28 In the present study, chronic GVHD occurred at a relatively high rate in view of the lower numbers of T cells administered, but pancytopenia was not observed in any patient. Regarding the timing of immunotherapy of 2.9-7.3 months post-SCT in this study, the probable explanation for the higher incidence of chronic GVHD was the early immunotherapy after SCT. In this respect, the results of the present study suggest that the time interval from SCT to immunotherapy may be an important safety factor in terms of the immunotherapy. Furthermore, the two cases with TRM underline this conclusion.
The fact that several patients receiving immunosuppressant withdrawal alone achieved MR, which persisted for as long as 30 months, without severe therapy-related toxicity, was interesting. So also was the fact that imatinib mesylate induced molecular or cytogenetic remission in refractory cases without fatal marrow aplasia or severe GVHD. Imatinib mesylate in post transplant relapse has been reported to be very effective and to be associated with lower toxicities and rare drug-associated mortality. [23] [24] [25] [26] Based on these results and our own experience, treatment with imatinib mesylate alone may be most reasonable during the early relapse period, especially when GHVD persists at the time of disease recurrence.
Previous studies have shown that patients with CRel or MRel have a higher rate of complete remission and lower side effects, such as GHVD or marrow aplasia, than those with hematological relapse. 5, 14, 21, 22 Remission rates of DLI for early-phase relapse were reported to be 82-100%, 5, [13] [14] [15] [16] which are higher than the 65% of the present study. However, several points should be considered when comparing our results with previous results. First, reduced intensity immunotherapy was used in this study, that is, immunosuppressant withdrawal alone or just one course of a low number of T cells, except in one case, and even in this case the second dose was relatively low. Second, remission was strictly defined in the present study; that is, we used MR, whereas most previous studies have used cytogenetic remission. Third, the nature of the disease in the present study might have carried a high risk for relapse, because all cases showed rapidly advancing relapse within a median of 3 months after SCT. In terms of these factors, relatively nonintensive immunotherapy might be feasible for treating early relapse.
By analyzing early-period relapse after SCT, we found that Q-RT-PCR was useful for detecting early relapse, but immunotherapy to prevent disease progression did not result in improved treatment outcome. We conclude that therapeutic intervention soon after transplantation should be weighted against its toxicity and that new approaches are needed to control rapidly advancing disease. Further studies are needed to validate the role of imatinib mesylate alone or in combination with immunotherapy in these settings.
